Publicacions en col·laboració amb investigadors/es de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (28)

2024

  1. Dendritic Cells in Cancer Immunology and Immunotherapy

    Cancers, Vol. 16, Núm. 5

  2. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort

    Science Advances, Vol. 10, Núm. 28

  3. Relevance of mutation-derived neoantigens and non-classical antigens for anticancer therapies

    Human Vaccines and Immunotherapeutics, Vol. 20, Núm. 1

2023

  1. Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism

    Gut

  2. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies

    Frontiers in Immunology, Vol. 13

  3. Erratum: Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies(Front. Immunol., (2023), 13, (1044025), 10.3389/fimmu.2022.1044025)

    Frontiers in Immunology

  4. Mutated trimeric RBD vaccines: a platform against variants of concern

    Signal Transduction and Targeted Therapy

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. Identification of HLA class I-restricted immunogenic neoantigens in triple negative breast cancer

    Frontiers in Immunology, Vol. 13

  3. Metformin keeps CD8+ T cells active and moving in NASH-HCC immunotherapy

    Journal of Hepatology

  4. Neoantigens as potential vaccines in hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2

  5. Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

2021

  1. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy

    Cancer Letters, Vol. 499, pp. 279-289

  2. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses

    Emerging Microbes and Infections, Vol. 10, Núm. 1, pp. 1931-1946

  3. The mutational load and a T-cell inflamed tumour phenotype identify ovarian cancer patients rendering tumour-reactive T cells from PD-1+ tumour-infiltrating lymphocytes

    British Journal of Cancer, Vol. 124, Núm. 6, pp. 1138-1149

  4. The tgf-β pathway: A pharmacological target in hepatocellular carcinoma?

    Cancers, Vol. 13, Núm. 13

2020

  1. Cold‐inducible rna binding protein as a vaccination platform to enhance immunotherapeutic responses against hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 11, pp. 1-18

2015

  1. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

  2. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88